Onyx Pharmaceuticals, Inc. (ONXX) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-86.84M
Realized gains on sales of current marketable securities
Depreciation and amortization
Stock-based compensation	21.85M
Amortization of convertible senior notes discount and debt issuance costs	6.3M
Changes in fair value of liability for contingent consideration
Property and equipment write-off
Impairment of equity investment
Restricted cash
Receivable from collaboration partners	-52.19M
Prepaid expenses and other current assets	10.63M
Other assets	-817K
Accounts payable	2.56M
Accrued liabilities	-3.93M
Accrued clinical trials and related expenses	-1.83M
Accrued compensation	-7.08M
Escrow liability
Lease termination exit costs liability
Other liabilities	961K
Net cash used in operating activities
Purchases of marketable securities	-276.27M
Sales of marketable securities	16.18M
Maturities of marketable securities	165.96M
Transfers from restricted cash
Payment for liability for contingent consideration, current
Capital expenditures
Net cash provided by investing activities
Repurchases of restricted stock awards
Net proceeds from issuances of common stock	389.6M
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period	153.24M
Cash and cash equivalents at end of period	323.07M
Cash paid during the period for income taxes	34K
Cash paid during the period for interest	4.6M

Entities mentioned with ONXX

View All Entities